FIELD: biotechnology.
SUBSTANCE: providing in eukaryotic cell a sequence of RNA guide complementary to nucleic acid target sequence, wherein the RNA guide sequence is bound to the target nucleic acid target sequence, and providing in eukaryotic cell protein Cas9, modified protein Cas9 or homologue of protein Cas9, which interacts with sequence of guiding RNA, where cell is not cell of human germ line.
EFFECT: disclosed is a method of genetic change of a eukaryotic cell.
25 cl, 15 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| RNA-GUIDED HUMAN GENOME ENGINEERING | 2013 |
|
RU2766685C2 |
| GENOMIC ENGINEERING | 2014 |
|
RU2688462C2 |
| GUIDED RNA TRANSCRIPTION REGULATION | 2014 |
|
RU2690935C2 |
| MULTIPLEX GENOMIC ENGINEERING GUIDED BY RNA | 2014 |
|
RU2764637C2 |
| MULTIPLEX RNA-GUIDED GENOME ENGINEERING | 2014 |
|
RU2706562C2 |
| GENOME ENGINEERING | 2021 |
|
RU2812848C2 |
| GENOMIC ENGINEERING | 2014 |
|
RU2764757C2 |
| RNA-GUIDED TRANSCRIPTION REGULATION | 2014 |
|
RU2756865C2 |
| CRISPR-CAS SYSTEM COMPONENTS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION | 2013 |
|
RU2701662C2 |
| DELIVERY AND USE OF SYSTEMS OF CRISPR-CAS, VECTORS AND COMPOSITIONS FOR TARGETED ACTION AND THERAPY IN LIVER | 2014 |
|
RU2716420C2 |
